Molecular Profiling for Neoadjuvant Therapy Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for head and neck squamous cell carcinoma (HNSCC), particularly HPV-negative cases, face challenges in improving recurrence-free survival and response to neoadjuvant anti-PD-1 therapy, with existing methods often resulting in unnecessary toxicity and delayed surgery without clear benefits.
Innovation Solution
The development of personalized treatment methods involving molecular marker analysis to distinguish between responders and non-responders to neoadjuvant anti-PD-1/L1 therapy, tailoring treatment based on tumor and blood molecular profiles, including tumor mutational burden, specific mutations, T cell ratios, and T cell receptor diversity, to guide the decision for surgery and adjuvant therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If neoadjuvant anti-PD-1 therapy is administered to all patients with resectable HNSCC, then some patients may benefit from improved recurrence-free survival, but many patients experience unnecessary toxicity and delayed surgery without clear benefits
Solution Approach 1:
The patent applies local quality by identifying specific molecular characteristics (TMB thresholds, TREG/TH17 ratios, TCR diversity metrics) that distinguish patients who will respond to anti-PD-1 therapy from those who will not. This allows the treatment benefit to be concentrated in the responsive subgroup while avoiding unnecessary toxicity in non-responsive patients.
Solution Approach 2:
The patent uses parameter changes by measuring and comparing multiple molecular parameters (tumor mutational burden, T cell ratios, TCR diversity) before treatment to predict response. These parameter assessments enable selection of patients whose molecular profiles indicate likely benefit from neoadjuvant therapy.
2Reliability
If neoadjuvant anti-PD-1 therapy is delayed or skipped for non-responders, then surgery can proceed without delay, but without molecular profiling, responders are missed and do not receive the potential survival benefit
Solution Approach 1:
The patent applies preliminary action by performing molecular profiling (assaying TMB, T cell ratios, and TCR diversity in tumor and blood samples) before deciding on neoadjuvant therapy. This preliminary assessment allows the treatment plan to be optimized in advance, ensuring responders receive therapy while non-responders proceed directly to surgery without delay.
Solution Approach 2:
The patent uses feedback by comparing molecular parameters from baseline samples with post-treatment samples to assess response. This feedback mechanism confirms whether the neoadjuvant therapy is having the desired effect, allowing for real-time treatment optimization.
3Adaptability or versatility
If comprehensive molecular profiling is performed on all patients, then treatment can be precisely tailored to individual profiles, but the complexity and cost of testing increases significantly
Solution Approach 1:
The patent applies segmentation by dividing the molecular profiling into distinct, measurable components: TMB assessment, TREG/TH17 ratio measurement, and TCR diversity evaluation. Each component can be assayed separately using established laboratory techniques, making the overall complex process manageable and implementable in clinical settings.
Data Source
AI summary
Methods of treating resectable head and neck cancer based on analyses of blood and tumor samples collected over the course of a clinical trial and during follow-up after the clinical trial. Omic or multi-plex molecular tools were used to analyze the tissues and identify objective molecular markers and pathogenic mechanisms associated with favorable or unfavorable outcomes. These analyses form the basis for a treatment strategy that improves outcomes by tailoring the treatment to the molecular features of individual patients' blood samples and tumors. This method for personalized treatment distinguishes between subjects who respond to neoadjuvant anti-PD-1/L1 therapy and patients who do not respond to such neoadjuvant therapy, so that treatment is tailored to the subject's responder profile. This approach avoids exposing patients to unnecessary toxicity, and avoids delaying surgical resection when no advantage will be gained by delaying surgery to allow for neoadjuvant therapy.